CSF3R and chronic myelomonocytic leukemia: However, the clinical impact of these mutations remains unknown and larger series of myeloid neoplasia are necessary to define the effect of CSF3R mutations on clinical outcome in patients with AML and CMML and to assess the therapeutic potential of kinase inhibitors (in particular, ruxolitinib or dasatinib) targeting CSF3R mutations.